ERBB2 and breast cancer: In addition to the whole MBC population, analysis has focused on relevant categories of clinical interest: De novo and bone-only MBC, endocrine resistance, patients treated with targeted agents (mTOR, CDK4/6, HER2 inhibitors), chemo-resistant TNBC and BC with late relapse.